Tenaya Therapeutics, Inc.

Stocks

Real-time Estimate Cboe BZX Other stock markets 03:03:52 2026-07-13 pm EDT			5-day change	1st Jan Change
0.8150 ^USD	-6.36%		-5.02%	+15.53%

Jun. 29	Tenaya Therapeutics, Inc. Announces Management Changes, Effective July 13, 2026	CI
Jun. 29	Tenaya Therapeutics, Inc. Announces Chief Financial Officer Changes, Effective July 13, 2026	CI

Published on 06/05/2026 at 05:05 pm EDT

S&P Capital IQ

Presenter Speech
Xander Guarna (Analysts)

My name is Xander Guarna from the Jefferies Healthcare Investment Banking team, and it's my pleasure to introduce Faraz Ali from Tenaya Therapeutics.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Jun. 29	Tenaya Therapeutics, Inc. Announces Management Changes, Effective July 13, 2026	CI
Jun. 29	Tenaya Therapeutics, Inc. Announces Chief Financial Officer Changes, Effective July 13, 2026	CI
Jun. 29	Tenaya Therapeutics Names Eric Hyllengren CFO	MT
Jun. 05	Tenaya Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-04-2026 03:10 PM
Jun. 03	Tenaya Therapeutics, Inc. - Special Call
Jun. 02	Tenaya Therapeutics, Inc. Announces New Interim Data From MyPEAK-1 Phase 1b/2 Trial Of TN-201 For Adults With MYBPC3-Associated HCM	CI
May. 15	Tenaya Therapeutics, Inc. - Special Call
May. 15	Positive interim data from cohorts 1 and 2 of Tenaya's Ridge-1 phase 1b/2 clinical trial of TN-401	RE
May. 15	Tenaya Therapeutics Presents Interim Data From Ridge-1 Phase 1b/2 Clinical Trial Of TN-401 Gene Therapy For PKP2-Associated ARVC	CI
May. 06	Tenaya Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 27	Tenaya Therapeutics Announces New Clinical Data and Pipeline Innovations	CI
Mar. 18	Tenaya Therapeutics, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-09-2026 01:00 PM
Mar. 11	Tenaya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 09	Tenaya Therapeutics Presents Preclinical Data Highlighting Tn-301?S Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy	CI
Mar. 05	Tenaya Therapeutics and Alnylam Pharmaceuticals Enter Research Collaboration Agreement	CI